SYNCOM FORMULATIONS (INDIA)
Back to Balance Sheet
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Total Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2017 | Mar2016 | |
---|---|---|---|---|---|
Total Liabilities | ₹405 Cr | ₹378 Cr | ₹308 Cr | ₹184 Cr | ₹181 Cr |
What is the latest Total Liabilities ratio of SYNCOM FORMULATIONS (INDIA) ?
Year | Total Liabilities |
---|---|
Mar2024 | ₹405 Cr |
Mar2023 | ₹378 Cr |
Mar2022 | ₹308 Cr |
Mar2017 | ₹184 Cr |
Mar2016 | ₹181 Cr |
How is Total Liabilities of SYNCOM FORMULATIONS (INDIA) Trending?
Years | Total Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹405 Cr | 7.10 | |
Mar2023 | ₹378 Cr | 22.58 | |
Mar2022 | ₹308 Cr | 67.59 | |
Mar2017 | ₹184 Cr | 1.81 | |
Mar2016 | ₹181 Cr | - |
Compare Total Liabilities of peers of SYNCOM FORMULATIONS (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
SYNCOM FORMULATIONS (INDIA) | ₹2,014.4 Cr | 1% | 42.4% | 81.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹406,519.0 Cr | 1.6% | -2.9% | 17.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹175,903.0 Cr | 1.5% | 10.4% | 51.9% | Stock Analytics | |
CIPLA | ₹121,669.0 Cr | 2.3% | 1.9% | 2.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹110,097.0 Cr | 5.7% | 14.1% | 15.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹107,605.0 Cr | 1.4% | 1.3% | 17% | Stock Analytics |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SYNCOM FORMULATIONS (INDIA) | 1% |
42.4% |
81.3% |
SENSEX | 1.3% |
2.6% |
7.8% |
You may also like the below Video Courses